Gunnar Esiason and Bob Coughlin, the former CEO of MassBio, talk about the state of the biotechnology industry in the background of the COVID-19 pandemic. Bob shares why the biotechnology trade association is important for biotech companies in Massachusetts, before getting into the industry’s reputation and how he thinks the pandemic will impact the way people view drug makers. Gunnar talks about why he thinks patients should be able to own clinical trial data, why clinical trials are not accessible enough for diverse patient populations, and how patients should be included throughout the drug development process.
State of Health Episode 5: Three Questions with Bob Coughlin from MassBio
